CTOs on the Move

MaxThera

www.maxthera.com

 
MaxThera, Inc. is a Beverly, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.maxthera.com
  • 100 Cummings Ctr Ste 419E
    Beverly, MA USA 01915
  • Phone: 978.927.8900

Executives

Name Title Contact Details

Similar Companies

Alpharma Integrated Solutions

Alpharma Integrated Solutions is a Vega Baja, PR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alaven Pharmaceutical

Alaven Pharmaceutical is a Marietta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Edgewise Therapeutics

Edgewise Therapeutics is a biotechnology company harnessing proven expertise and understanding of skeletal muscle physiology to develop novel, transformative therapies for serious muscle diseases. Based in Boulder, Colorado, we have built a state-of-the-art muscle research facility to capitalize on new insights into the nature and consequences of muscle adaptation and injury with disease. Edgewise recently closed it`s Series B financing round which will support the advancement of Edgewise Therapeutic`s lead product candidate into clinical development for Duchenne and Becker Muscular Dystrophy (DMD and BMD) as well as expansion of the company`s pipeline. The company`s leadership team has founded multiple biotechnology startups, several of which have gone on to become publicly-traded companies and brings to bear a depth of experience in drug discovery, development and commercialization.

Innovative Cellular Therapeutics

Innovative Cellular Therapeutics (ICT) is a private clinical stage biotechnology company headquartered in Rockville, MD. ICT is focused on the development of cellular immunotherapies for the treatment of solid tumors. ICT`s unique CoupledCAR® technology platform is designed to overcome the common challenges of treating solid tumors. ICT has achieved promising preclinical and proof-of-concept clinical results in late-stage solid tumors, such as colorectal cancer and thyroid cancer. The U.S. Food and Drug Administration (FDA) has provided a Study-May-Proceed letter for the Company`s Investigational New Drug (IND) application for a Phase 1 clinical trial of GCC19CART targeting relapsed and refractory metastatic colorectal cancer. ICT expects to initiate this U.S. focused clinical trial, referred to as CARAPIA-1, in the summer of 2022. The Company has a broad pipeline of CAR-T candidates targeting additional solid tumors.

Sirion Therapeutics

Sirion Therapeutics, Inc. is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.